Hey Koo, if the major shareholders and management were motivated to reunite the two operating entities the fact that there are a variety of shareholders does not in and of itself present an issue, the real challenge would be ascertaining the relative values of RVX and ZEL respectively. IMO this challenge could be fairly met because the two largest shareholders have somewhat diverging interests when it comes to valuation in this scenario. Eastern, owning a larger proportional interest in ZEL would likely want to see the highest possible relative valuation for ZEL where Hepalink, currently not holding Zenith shares, would obviously like to see a valuation favouring RVX. After the relative valuation is established the rest is just basic math. Although I'm not really expecting this type of transaction to occur I do think it is a practical way to resolve the issues outlined in my first post. An additional bonus would be Hepalink being involved with all the related IP. Being the only corporate entity in the mix with real pharma experience and perspective I think Hepalink's involvement with everything would be nothing but beneficial both from an operational and credibility perspective.